Sedative, Hypnotic, or Anxiolytic Use Disorder

Sedative, hypnotic, or anxiolytic use disorder is a clinical diagnosis describing a pattern of compulsive use of calming or sleep-inducing medications, from benzodiazepines and “Z-drugs” to older barbiturates, that continues despite significant harm. It is one of the substance use disorders defined in diagnostic manuals, and it captures a range of severity from mild problematic use to severe physical dependence with dangerous withdrawal. The condition has drawn increasing clinical attention because the drugs involved are among the most widely prescribed in the world, the brain adaptations they trigger can develop faster than many patients or prescribers expect, and stopping abruptly can be medically dangerous in ways that few other drug classes match.

Which Drugs Fall Under This Umbrella

The diagnostic category covers any substance whose primary action is to calm the nervous system or promote sleep. In practice, the vast majority of cases today involve benzodiazepines such as alprazolam, diazepam, clonazepam, and lorazepam. Close behind are the so-called Z-drugs, zolpidem, zopiclone, and zaleplon, which were marketed as safer alternatives to benzodiazepines for insomnia but share a very similar pharmacological profile and comparable dependence potential.¹ A cross-sectional study of chronic users found dependence rates of roughly 77% among benzodiazepine users and 69% among Z-drug users, with no statistically significant difference between the two groups. Barbiturates, which dominated the mid-twentieth century, are now rarely prescribed but still appear occasionally, and older agents like chloral hydrate are essentially historical footnotes.

A newer and more unpredictable threat comes from designer benzodiazepines, synthetic compounds structurally tweaked to sidestep drug scheduling laws. Between 2019 and early 2020, designer benzodiazepines were identified in nearly half of postmortem toxicology cases and over 80% of drugged-driving cases reported to the United Nations Office on Drugs and Crime, with flualprazolam, flubromazolam, and etizolam appearing most frequently.² These compounds vary wildly in potency and duration, and users often have no idea what they are actually consuming.

How the Brain Adapts and Why Dependence Develops

Benzodiazepines and Z-drugs work by amplifying the activity of GABA, the brain’s main inhibitory chemical messenger. Specifically, they latch onto a receptor and make GABA more effective at calming neural firing. The calming, sleep-promoting, muscle-relaxing, and anti-seizure effects all flow from this single mechanism. The problem is that the brain fights back. With repeated exposure, the receptor system shifts so that the drug’s boosting effect is blunted, a process researchers describe as a “withdrawal shift” in receptor function that occurs without any change in the number of receptors themselves.³ Research points to one particular receptor subtype, containing the alpha-1 subunit, as playing a central role in the reward-related brain changes that drive misuse and in the development of both tolerance and physical dependence.⁴

Animal studies fill in more detail. During the first few days of withdrawal from diazepam, expression of certain receptor subunits shifts, and the brain’s own GABA-producing machinery ramps up as if trying to compensate. Meanwhile, excitatory signaling through a different receptor system appears to drive the acute withdrawal symptoms people actually feel, like agitation and seizures.⁵ This is why withdrawal from these drugs can be so physically intense: the brain has dialed down its own calming machinery and, once the drug is removed, the excitatory side runs unchecked.

Tolerance Does Not Develop Evenly

One of the more counterintuitive findings about this class of drugs is that tolerance develops at different speeds for different effects. People tend to become tolerant to the sedative and anticonvulsant effects fairly quickly, sometimes within days to weeks of daily use. But tolerance to the anti-anxiety effect may not develop at all, or develops far more slowly.⁶ This creates a clinical trap: a person prescribed a benzodiazepine for anxiety may still feel the anxiety relief at the same dose, so both they and their prescriber assume the drug is working fine. Meanwhile, the brain has already adapted to the sedative effect, physical dependence has set in, and stopping the drug would produce withdrawal.

Primate research confirms this uneven pattern. In rhesus monkeys given daily alprazolam, the visibly sedating effects faded over time while sleep-related postures persisted or even increased, and abrupt cessation triggered clear physical withdrawal signs.⁷ The practical lesson is that feeling less drowsy on a stable dose does not mean the body is not dependent.

Why Withdrawal Can Be Dangerous

Benzodiazepine withdrawal stands apart from withdrawal from most other drug classes because it can cause seizures and, in severe cases, death. Withdrawal seizures have been reported with short-acting, medium-acting, and long-acting benzodiazepines if discontinued suddenly. They usually occur after prolonged high-dose use, but have also been documented after as little as two weeks at normal therapeutic doses.⁸ Nearly all reported withdrawal seizures are generalized tonic-clonic events, the convulsive kind, and severity ranges from a single episode to status epilepticus and coma.

Beyond seizures, withdrawal commonly produces severe insomnia, intense anxiety that often exceeds the original condition, perceptual disturbances, tremor, nausea, and a global sense of unreality that patients frequently describe as among the worst experiences of their lives. These symptoms can last weeks and sometimes months, particularly after long-term use, because the receptor changes the brain made to accommodate the drug take a long time to reverse.

The Opioid Overlap and Overdose Risk

A disproportionate share of the harm from sedative-hypnotic use disorder comes not from benzodiazepines alone but from their combination with opioids. People who use both classes together often report seeking out benzodiazepines specifically to intensify the opioid high or to manage the anxiety and insomnia that accompany opioid use.⁹ The combination is particularly lethal because the two drug classes suppress breathing through partly independent mechanisms that stack on top of each other. Animal research shows that combining a benzodiazepine with an opioid produces respiratory depression far greater than either drug alone, with some effects on breathing parameters being genuinely non-additive, meaning the combined effect is worse than you would predict by simply adding the two individual effects together.¹⁰

The motor impairment caused by the combination adds another layer of danger. In studies with rats, combining heroin and midazolam caused such severe loss of motor control that some animals collapsed in positions that blocked their airways, producing a secondary wave of oxygen deprivation unrelated to the direct respiratory depression.¹¹ The human parallel is a person who loses consciousness in a position that occludes breathing, a scenario that emergency responders encounter regularly.

Among people who use both opioids and benzodiazepines, the co-use is strongly associated with greater anxiety and depression, higher rates of PTSD symptoms, and a low perception of how risky the combination actually is.¹² Rural populations show their own pattern: benzodiazepine-opioid co-users in one large rural study were more likely to also misuse prescription pain pills and gabapentin to get high, and they reported more frequent heavy drinking compared with people combining stimulants and opioids.¹³

Who Is Being Diagnosed

Nationwide Medicaid data show that diagnosed sedative-hypnotic or anxiolytic use disorder has been climbing among young people. Among adolescents enrolled in Medicaid, the diagnosis rate quadrupled between 2001 and 2009. Among young adults, it rose from 0.05% in 2001 to 0.24% by 2019, a nearly fivefold increase over roughly two decades.¹⁴ Whether these numbers reflect a true increase in problematic use, better screening, or both is debated, but the trend is consistent and statistically robust. These figures also undercount the problem because they capture only people who received a formal diagnosis through Medicaid-reimbursed care and miss anyone with private insurance, no insurance, or undiagnosed use.

Older Adults Face Compounding Risks

People over 65 are a population where benzodiazepine prescribing is especially fraught. The drugs are metabolized more slowly with age, receptor sensitivity changes, and the consequences of side effects are more severe. A large population-based study found that older adults taking long-acting benzodiazepines had roughly double the risk of falls or fractures, and the risk remained elevated and actually grew the longer the prescription continued.¹⁵ A systematic review confirmed that benzodiazepine exposure consistently raises fall risk in older adults, whether used alone or alongside other medications, and recommended short-acting agents if a benzodiazepine is deemed unavoidable.¹⁶

Falls are not the only concern. A growing body of evidence suggests benzodiazepine use in older adults is associated with cognitive decline, and may be a modifiable risk factor for dementia including Alzheimer’s disease, although the evidence on causation remains mixed and newer studies are working to untangle whether the drugs themselves cause cognitive damage or whether early dementia symptoms drive benzodiazepine prescribing in the first place.¹⁷ Despite strong guideline recommendations against chronic benzodiazepine use in people over 65, a substantial proportion of older Americans continue to take them long-term.

How Tapering Works in Practice

Because abrupt discontinuation can trigger seizures and other dangerous withdrawal effects, the standard approach to stopping a benzodiazepine is a gradual taper. A recent clinical practice guideline recommends starting with dose reductions of 5 to 10% every two to four weeks, and advises against reducing faster than 25% every two weeks. The taper may go faster for people who have been on the drug for less than about three months, and slower for long-term users. In some cases, the goal is not necessarily complete discontinuation but rather reducing the dose to a level where the ongoing risks no longer outweigh the benefits.¹⁸ Clinicians are also encouraged to consider switching patients to a longer-acting benzodiazepine for the taper, since longer-acting agents produce more stable blood levels and smoother withdrawal.

This is where patient experience and clinical guidelines sometimes collide. Many people attempting a taper report that their prescribers move too fast, underestimate the severity of protracted withdrawal symptoms, or lack familiarity with gradual tapering protocols. Online communities of people going through benzodiazepine tapering have become an important source of peer support and practical knowledge-sharing, reflecting widespread frustration with the clinical support available.

Medications That May Help During Withdrawal

There is no FDA-approved medication specifically for sedative-hypnotic withdrawal the way there are approved treatments for opioid or alcohol use disorders. The mainstay of withdrawal management is the taper itself, using the benzodiazepine to manage its own withdrawal. Adjunctive medications are used experimentally, and the evidence is still evolving.

Gabapentin has attracted the most interest. A retrospective study found that patients experiencing benzodiazepine withdrawal who received gabapentin alongside their tapering benzodiazepine used less total benzodiazepine and had shorter hospital stays.¹⁹ However, the picture is not straightforward. A pilot trial testing gabapentin specifically for benzodiazepine dependence in people on methadone maintenance found no significant differences in benzodiazepine use or withdrawal severity between the gabapentin and placebo groups.²⁰ Gabapentin itself carries some misuse potential, which complicates its use in this population, particularly among people who also use opioids. Other medications tried in various settings include anticonvulsants like carbamazepine and certain antidepressants, but none has strong enough evidence to be considered a standard treatment.

Cognitive Behavioral Therapy as a Taper Companion

The strongest behavioral evidence for this disorder comes from studies pairing a gradual taper with cognitive behavioral therapy. In patients with panic disorder who were tapering off benzodiazepines, adding CBT produced consistently medium-to-large advantages over tapering alone, with the benefits becoming most pronounced by the six-month follow-up. CBT also outperformed taper combined with relaxation training, suggesting the benefit is specific to the CBT approach rather than just having a therapist in the room.²¹ Across the research literature, CBT-assisted discontinuation programs have been reported to raise abstinence success rates to the range of 70 to 80%.²²

This makes intuitive sense. Many people on long-term benzodiazepines originally started them for anxiety or insomnia, and the prospect of tapering off reactivates those underlying fears. CBT directly addresses the catastrophic thinking that fuels both the original anxiety and the fear of withdrawal, giving people concrete skills to manage symptoms that the benzodiazepine was masking. Acceptance and commitment therapy has also shown promise in early studies, though the evidence base is thinner.

Do Prescription Monitoring Programs Help

Many U.S. states have implemented prescription drug monitoring programs, or PDMPs, that require prescribers to check a centralized database before writing controlled-substance prescriptions. The evidence on whether these mandates actually reduce problematic benzodiazepine use is surprisingly mixed. A national analysis of Medicaid enrollees found that state PDMP mandates for benzodiazepines were not associated with reductions in the quantity, dosage, or spending on benzodiazepine prescriptions.²³

Where the programs have shown clearer results is in reducing the overlap between opioid and benzodiazepine prescriptions, which is arguably the more dangerous target. Kentucky’s PDMP mandate was associated with an immediate 7.5% drop in the rate of overlapping benzodiazepine-opioid prescriptions, and over a full year, new overlapping prescriptions fell by about 29%.²⁴ Ohio saw a statistically significant decrease in the monthly volume of both opioids and benzodiazepines dispensed after its own mandatory PDMP review law took effect.²⁵ The takeaway is that these monitoring systems seem to work better at flagging dangerous drug combinations than at curbing benzodiazepine prescribing overall.

The Gap Between Prescribing Culture and the Science of Dependence

A persistent oddity in medicine is that benzodiazepines continue to be prescribed as if they were routine maintenance medications for anxiety and insomnia, even though the evidence for long-term benefit is thin and the evidence for long-term harm is substantial. Guidelines across multiple medical societies recommend benzodiazepines only for short-term use, typically two to four weeks, yet real-world prescribing patterns show millions of people taking them for months or years. This disconnect exists partly because the drugs work dramatically well in the short term, partly because withdrawal makes stopping difficult, and partly because physicians who inherited a long-term patient often face the choice between continuing a problematic prescription and precipitating a withdrawal crisis in their office.

The Z-drugs have followed a similar trajectory. They were introduced in the 1990s with the explicit promise of less dependence liability than benzodiazepines, but head-to-head comparisons of chronic users show no meaningful difference in dependence rates.²⁶ Both drug classes act on the same receptor system, and the brain’s adaptation does not particularly care about the marketing materials. This does not mean Z-drugs and benzodiazepines are identical in every respect, but it does mean the “safer alternative” framing that many prescribers and patients still hold is largely a myth when it comes to dependence after chronic use.²⁷

For the person who finds themselves already physically dependent on one of these medications, the most important thing to know is that stopping should be done gradually and with medical oversight. A slow taper, ideally paired with therapy to address the underlying condition the drug was originally prescribed for, offers the best odds of a successful outcome. And for prescribers, the research increasingly argues that the conversation about an exit plan should happen at the very first prescription, not months or years later when the brain has already remodeled itself around the drug.